Genomic diagnostics company making tests that predict recurrence risk for skin cancers and other dermatologic and eye conditions.
Genomic diagnostics company making tests that predict recurrence risk for skin cancers and other dermatologic and eye conditions.
Is paid per test by Medicare and private insurers rather than by the doctors who order them, so coverage decisions and the share of claims actually reimbursed matter as much as test volume. The melanoma and skin-cancer tests carry the business, with newer tests in other conditions still being established.
Moat: narrow (IP / patents, data). Proprietary gene-expression tests built on clinical outcome data guide treatment decisions, hard to replicate quickly.
Headquarters: Friendswood, Texas · Founded: 2007 · Employees: 883
Size Castle Biosciences (CSTL) is a United States Health Care company (Medical Specialties) with a market value of $1.03B, the 2216th largest of 3,085 United States companies the cockpit tracks. Shares closed at $33.38 on 18 Nov 2026.
Performance Over six months the shares gained 66.7%, against -7.9% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 9.8% over the last twelve months (peer median +12.3%); the operating margin is -7.4% (peer median 11.6%).
Valuation It trades at 2.1× enterprise value to sales against a peer median of 3.9× (6th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 19.2 points below its cost of capital (9.9% WACC).
Short interest Short interest is 6.8% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $377M | $344M | $332M | $220M | $137M |
| Revenue growth | — | +4% | +51% | +60% | — |
| Gross profit | $279M | $236M | $259M | $164M | $95.4M |
| EBITDA | -$12.1M | -$2.04M | $24.7M | -$55.6M | -$80.6M |
| Net income | -$23.0M | -$24.2M | $18.2M | -$57.5M | -$67.1M |
| Free cash flow | $3.96M | $28.3M | $43.2M | -$13.8M | -$45.9M |
| Capital expenditure | $35.8M | $36.0M | $28.3M | $13.6M | $5.63M |
| Total debt | $36.6M | $37.0M | $26.4M | $15.3M | $13.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Castle Biosciences CSTL | $1.03B | +67% | +10% | -7% | 2.1× | 57.7% |
| Myriad Genetics MYGN | $530M | +45% | -3% | -13% | 0.8× | n/a |
| Veracyte VCYT | $2.06B | -43% | +18% | 16% | 3.0× | 18.0% |
| Natera NTRA | $42.0B | +41% | +37% | -9% | 14.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CSTL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.7% | -5.1% | 9th highest of 21 |
| 6-month return | +66.7% | -7.9% | highest of 20 |
| Distance from 52-week high | -24.6% | -28.9% | 9th highest of 21 |
| Revenue growth (TTM) | +9.8% | +12.3% | 8th lowest of 19 |
| Operating margin | -7.4% | 11.6% | 5th lowest of 20 |
| EV / Sales | 2.1× | 3.9× | 6th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 57.7% | 5.9% | most demanding of 14 |
| Growth delivered (Del g) | +40.6% | +10.4% | highest of 14 |
| Hurdle (Req g minus delivered) | +17.1 pp | -3.4 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | -19.2 pp | +8.0 pp | 3rd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | 2.1× | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 2.7× | 7.7% | +12.1% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | 3.0× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | 11.1× | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 0.9× | -4.0% | +3.5% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 4.7× | 4.9% | +10.4% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 11.1× | 18.5% | +21.5% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 2.5× | 6.9% | -2.9% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | 4.3× | n/a | n/a |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | 8.3× | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | 85.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 6.3× | 8.8% | +8.8% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 3.1× | 10.7% | +12.9% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 1.7× | 5.9% | +3.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 4.0× | -9.2% | +34.5% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | 4.7× | n/a | n/a |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 1.9× | n/a | n/a |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 3.9× | 3.3% | +13.9% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 1.3× | -6.1% | +11.7% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 0.9× | 1.3% | +4.7% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |